Curadev Pharma has entered into a research collaboration and license agreement with Roche for development and commercialization of IDO1 and TDO inhibitors.
The agreement covers the development of the lead preclinical immune tolerance inhibitor and a research collaboration with Roche's research and early development organization to further explore the IDO and TDO pathways.
|Searching for more deal information? Current Partnering offers the following options:
Under the terms of agreement, which includes a research collaboration with Roche's research and early development organization to further extend Curadev's findings, Curadev will receive an upfront payment of $25 million and will be eligible to receive up to $530 million in milestone payments based on achievement of certain predetermined events and sales levels as well as escalating royalties potentially reaching double digits for the first product from the collaboration developed and commercialized by Roche.
Curadev would also be eligible for milestones and royalties on any additional products resulting from the research collaboration.
Roche will fund future research, development, manufacturing and commercialization costs and will also provide additional research funding to Curadev for support of the research collaboration.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies